Cargando…

Drug–Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly

Overactive bladder (OAB) is characterized by urinary urgency and increased urinary frequency, substantially affecting quality of life. Tamsulosin and mirabegron combination therapy has been studied as a safe and effective treatment option for patients with OAB. This study evaluated the effects of co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Wonsuk, Yang, A-Young, Yoo, Hyounggyoon, Kim, Anhye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610014/ https://www.ncbi.nlm.nih.gov/pubmed/37895930 http://dx.doi.org/10.3390/ph16101457

Ejemplares similares

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State
por: Shin, Wonsuk, et al.
Publicado: (2023)

Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation
por: Yang, A-Young, et al.
Publicado: (2023)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Development of Green HPTLC method for simultaneous determination of a promising combination Tamsulosin and Mirabegron: stability-indicating assay was examined
por: Abou El-Alamin, Maha M., et al.
Publicado: (2023)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
por: Su, Shunye, et al.
Publicado: (2020)

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy
por: Kang, Tae Wook, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

A Case of Mucosal Fixed Drug Eruption Caused by Tamsulosin Administration
por: Choi, Hoon, et al.
Publicado: (2022)

Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study
por: Katoh, Takao, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Comparison of international guidelines for early-phase clinical trials of cellular and gene therapy products
por: Shin, Wonsuk, et al.
Publicado: (2022)

Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate
por: Lee, Hong-Goo, et al.
Publicado: (2019)

Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
por: Dąbrowska, Anna Maria, et al.
Publicado: (2023)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Physicochemical and Pharmacokinetic Parameters in Drug Selection and Loading for Transdermal Drug Delivery
por: Chandrashekar, N. S., et al.
Publicado: (2008)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson, Debra J, et al.
Publicado: (2014)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2017)

Efficacy of Tamsulosin alone versus Tamsulosin Phloroglucinol combination therapy for medical expulsion of lower Ureteral calculi
por: Shafique, Muhammad Nadeem, et al.
Publicado: (2018)

A review of significant pharmacokinetic drug interactions with antidepressants and their management
por: Hoffelt, Charity, et al.
Publicado: (2016)

Editorial: Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites
por: Mircioiu, Constantin, et al.
Publicado: (2021)

Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions
por: Jakobsson, Gerd, et al.
Publicado: (2022)

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
por: Shin, Wonsuk, et al.
Publicado: (2019)

The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men
por: Nahon, Kimberly J., et al.
Publicado: (2020)

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
por: Das, Shampa, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetic Drug–Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers
por: Lee, Hae Won, et al.
Publicado: (2020)

Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults
por: Shimizu, Hidetoshi, et al.
Publicado: (2021)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fk58k8ks0f69ltti67eq6400ru